Acute parvovirus B19 infection during anti-retroviral therapy

Parvovirus B19 seroconversion in a cohort of human immunodeficiency virus-infected patients

“…In the medical literature, there are only reports of isolated cases, primarily after patients had begun HAART treatment (Bremner & Cohen 1994, Arribas et al 2000, Taguchi et al 2001, Ware & Moore 2001, Clarke & Lee 2003. The high rate of B19V seroconversion in the present study [28 (31.8%) out of 88 individuals] may be explained by the wide exposure of the population to this virus during the epidemic.…”

“…In the medical literature, there are only case reports about describing B19V seroconversion in HIV-positive patients and these have mostly occurred after the starting of HAART treatments (Bremner & Cohen 1994, Arribas et al 2000, Taguchi et al 2001, Ware & Moore 2001, Clarke & Lee 2003, Watanabe et al 2011. To better understand the importance of B19V infection in the HAART era, we conducted a study to estimate the frequency of B19V seroconversion in a cohort of HIVinfected patients.…”